Evidence map›Paper›PMID 36016250›Full record

ArticleVaccines2022

Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination.

Alok R Amraotkar, Adrienne M Bushau-Sprinkle, Rachel J Keith, Krystal T Hamorsky, Kenneth E Palmer, Hong Gao, Shesh N Rai, Aruni Bhatnagar

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alok R AmraotkarDivision of Environmental Medicine, Christina Lee Brown Envirome Institute, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.ORCID 0000-0001-7506-8673
Adrienne M Bushau-SprinkleCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Rachel J KeithDivision of Environmental Medicine, Christina Lee Brown Envirome Institute, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Krystal T HamorskyCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Kenneth E PalmerCenter for Predictive Medicine for Biodefense and Emerging Infectious Diseases, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Hong GaoDivision of Environmental Medicine, Christina Lee Brown Envirome Institute, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Shesh N RaiCenter for Integrative Environmental Health Sciences, Department of Medicine and Department of Biostatistics and Bioinformatics, University of Louisville School of Medicine, Louisville, KY 40202, USA.ORCID 0000-0002-8377-353X
Aruni BhatnagarDivision of Environmental Medicine, Christina Lee Brown Envirome Institute, Department of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
University of Louisville · US

Funding

CDC HHS 75D30121C10273James Graham Brown Foundation NoneLouisville-Jefferson County Metro Government component of the Coronavirus Aid, Relief, and Economic Security (CARES) ActOwsley Brown II Family Foundation None
6 · The paper itself

Abstract

backgroundThe impact of chronic health conditions (CHCs) on serostatus post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is unknown.

methodsWe assessed serostatus post-SARS-CoV-2 vaccination among fully vaccinated adult residents of Jefferson County, Kentucky, USA, from April 2021 to August 2021. Serostatus was determined by qualitative analysis of SARS-CoV-2-specific Spike IgG antibodies via enzyme-linked immunoassay (ELISA) in peripheral blood samples.

resultsOf the 5178 fully vaccinated participants, 51 were seronegative and 5127 were seropositive. Chronic kidney disease (CKD) and autoimmune disease showed the highest association with negative serostatus in fully vaccinated individuals. The absence of any CHC was strongly associated with positive serostatus. The risk of negative serostatus increased as the total number of pre-existing CHCs increased. Similarly, the use of two or more CHC-related medications was associated with seronegative status.

conclusionsThe presence of any CHC, especially CKD or autoimmune disease, increased the likelihood of seronegative status among individuals who were fully vaccinated to SAR-CoV-2. This risk increased with a concurrent increase in number of comorbidities, especially with multiple medications. The absence of any CHC was protective and increased the likelihood of a positive serological response. These results will help develop appropriate guidelines for booster doses and targeted vaccination programs.

Indexed as

antibody responsecomorbiditySARS-CoV-2 antibodyserologyserostatus

Identifiers

PMID36016250
PMCPMC9416221
OpenAlexW4292575519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.